WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Postmarket & security

THE TAPE

Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register Elucid raises $55M Series D with FFR-CT 510(k) under FDA review Enovis to buy eCential Robotics for 155 million euros FDA authorizes Vitestro's Aletta, the first autonomous blood-drawing robot, five months after a $70M Series B Renata Medical raises $25M Series D to scale the Minima pediatric stent FDA opens a docket on how to regulate generative AI devices FDA clears Jupiter Endovascular's Vertex thrombectomy system for pulmonary embolism in 89 days FDA clears Wandercraft's Eve, the first self-balancing exoskeleton for home use Meduloc raises $4M Series B to start alpha launch of its nitinol fracture implant FDA sets FY2027 device user fees: $28,653 for a 510(k), $13,785 to register

Series A

Ventaris Surgical raises $30M Series A for a ureteroscope built for complete stone clearance

MedDevice Startups Staff · Jan 9 · 2 min read · Via Company release (PR Newswire)

Ventaris Surgical raised $30 million in a Series A announced January 9, 2026. Longitude Capital led. Vensana Capital came in as a new investor, alongside Atypical Ventures, Neotribe Ventures and Boutique Venture Partners. Varun Gupta of Longitude and Justin Klein of Vensana joined the board, with Amir Abolfathi as an independent director.

The San Carlos, California company is developing a ureteroscopic system for kidney stone removal. The design targets the anatomy, stone burden, workflow constraints and surgeon fatigue that leave residual fragments after ureteroscopy. CEO Surag Mantri describes the goal as reliably achieving complete stone clearance. The device is investigational and not cleared by FDA; proceeds fund clinical development and regulatory and commercial milestones. A ureteroscope has predicates, so the pathway is likely a 510(k); the hard part is evidence for a residual-fragment claim.

Questions & Answers

How much did Ventaris Surgical raise in its Series A?

Ventaris Surgical raised $30 million in a Series A announced January 9, 2026. Longitude Capital led, Vensana Capital joined as a new investor, and Atypical Ventures, Neotribe Ventures and Boutique Venture Partners participated.

What is Ventaris Surgical developing?

Ventaris Surgical is developing a ureteroscopic system for kidney stone removal designed to achieve complete stone clearance. The device is investigational and not cleared by FDA; Surag Mantri is CEO.

← Back to Fundraising